Cargando…

First prospective outcome data for the second-generation multigene test Endopredict in ER-positive/HER2-negative breast cancer

PURPOSE: Prospectively collected outcome data of patients (pts) whose adjuvant systemic therapy recommendation was based on the clinico-molecular test EndoPredict(®) (EP) are presented. METHODS: Pts with ER-positive, HER2-negative early breast cancer with 0–3 positive lymph nodes were enrolled. The...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ettl, Johannes, Anders, Sophie-Isabelle, Hapfelmeier, Alexander, Paepke, Stefan, Noske, Aurelia, Weichert, Wilko, Klein, Evelyn, Kiechle, Marion
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2020
Materias:	Gynecologic Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7584549/ https://www.ncbi.nlm.nih.gov/pubmed/32902674 http://dx.doi.org/10.1007/s00404-020-05771-4

Ejemplares similares

Risk stratification in luminal-type breast cancer: Comparison of Ki-67 with EndoPredict test results
por: Noske, Aurelia, et al.
Publicado: (2019)

Decision impact and feasibility of different ASCO-recommended biomarkers in early breast cancer: Prospective comparison of molecular marker EndoPredict and protein marker uPA/PAI-1
por: Ettl, Johannes, et al.
Publicado: (2017)

Demand for integrative medicine among women in pregnancy and childbed: a German survey on patients’ needs
por: Schürger, Nikolas, et al.
Publicado: (2018)

Interassay and interobserver comparability study of four programmed death-ligand 1 (PD-L1) immunohistochemistry assays in triple-negative breast cancer
por: Noske, Aurelia, et al.
Publicado: (2021)

Demand for integrative medicine among women with breast and gynecological cancer: a multicenter cross-sectional study in Southern and Northern Germany
por: Grimm, Donata, et al.
Publicado: (2020)

Lifestyle modifications after the diagnosis of gynecological cancer
por: Paepke, Daniela, et al.
Publicado: (2021)

Use of biologically-based complementary medicine in breast and gynecological cancer patients during systemic therapy
por: Drozdoff, Loisa, et al.
Publicado: (2018)

Comparison of EndoPredict and Oncotype DX Test Results in Hormone Receptor Positive Invasive Breast Cancer
por: Varga, Zsuzsanna, et al.
Publicado: (2013)

The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2− breast cancer patients
por: Dubsky, P, et al.
Publicado: (2013)

Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-Positive, HER2-Negative Primary Breast Cancer
por: Constantinidou, Anastasia, et al.
Publicado: (2022)

Correction: Comparison of EndoPredict and Oncotype DX Test Results in Hormone Receptor Positive Invasive Breast Cancer
por: Varga, Zsuzsanna, et al.
Publicado: (2013)

Experience with oral emergency contraception since the OTC switch in Germany
por: Kiechle, Marion, et al.
Publicado: (2016)

Gynecologic oncologists’ attitudes and practices relating to integrative medicine: results of a nationwide AGO survey
por: Klein, Evelyn, et al.
Publicado: (2017)

Comparison of the RNA-based EndoPredict multigene test between core biopsies and corresponding surgical breast cancer sections
por: Müller, Berit Maria, et al.
Publicado: (2012)

Evaluation of an Expert Guided Integrative Therapy Concept in Patients With Breast or Gynecological Cancer During Systemic Therapy
por: Schmidt, Georg, et al.
Publicado: (2020)

Incidence and predictors for chemotherapy modifications and their impact on the outcome of ovarian cancer patients
por: Hatsy, Sandra, et al.
Publicado: (2022)

Decentral gene expression analysis for ER+/Her2− breast cancer: results of a proficiency testing program for the EndoPredict assay
por: Denkert, Carsten, et al.
Publicado: (2012)

Comparison of risk classification between EndoPredict and MammaPrint in ER-positive/HER2-negative primary invasive breast cancer
por: Peláez-García, Alberto, et al.
Publicado: (2017)

EndoPredict(®) in early hormone receptor-positive, HER2-negative breast cancer
por: Almstedt, K., et al.
Publicado: (2020)

EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer
por: Dubsky, P., et al.
Publicado: (2013)

Potential Interactions of Biologically Based Complementary Medicine in Gynecological Oncology
por: Drozdoff, Loisa, et al.
Publicado: (2019)

Neoadjuvant palbociclib on ER+ breast cancer (N007): clinical response and EndoPredict’s value
por: Chow, Louis W C, et al.
Publicado: (2017)

Independent Tissue-Based Biomarkers in Endometrioid Endometrial Cancer: Tumor Budding in Microsatellite Instability and WHO Grading in Copy-Number-Low Patients
por: Stögbauer, Fabian, et al.
Publicado: (2023)

Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2− breast cancer patients: results from the GEICAM 9906 trial
por: Martin, Miguel, et al.
Publicado: (2014)

Intracavitary brachytherapy with additional Heyman capsules in the treatment of cervical cancer
por: Scharl, Sophia, et al.
Publicado: (2022)

The multigene signature MammaPrint impacts on multidisciplinary team decisions in ER(+), HER2(−) early breast cancer
por: Exner, R, et al.
Publicado: (2014)

Clinical performance of an analytically validated assay in comparison to microarray technology to assess PITX2 DNA-methylation in breast cancer
por: Schricker, Gabriele, et al.
Publicado: (2018)

TP53 germline mutations in the context of families with hereditary breast and ovarian cancer: a clinical challenge
por: Grill, Sabine, et al.
Publicado: (2020)

Lysine-urethane-based tissue adhesion for mastectomy—an approach to reducing the seroma rate?
por: Boeer, B., et al.
Publicado: (2020)

Impact of Modified 2013 ASCO/CAP Guidelines on HER2 Testing in Breast Cancer. One Year Experience
por: Varga, Zsuzsanna, et al.
Publicado: (2015)

Characterization of Hormone Receptor and HER2 Status in Breast Cancer Using Mass Spectrometry Imaging
por: Gonçalves, Juliana Pereira Lopes, et al.
Publicado: (2023)

Early Accreta and Uterine Rupture in the Second Trimester
por: Ronen, Joshua A, et al.
Publicado: (2018)

Introducing a novel highly prognostic grading scheme based on tumour budding and cell nest size for squamous cell carcinoma of the uterine cervix
por: Jesinghaus, Moritz, et al.
Publicado: (2018)

Gynecologists’ attitudes toward and use of complementary and integrative medicine approaches: results of a national survey in Germany
por: Grimm, Donata, et al.
Publicado: (2020)

Paracentesis of an Ovarian Cyst During Second-Trimester Pregnancy
por: Galatis, Dionysios, et al.
Publicado: (2021)

Medical abortion with mifepristone and home administration of misoprostol up to 63 days’ gestation
por: Løkeland, Mette, et al.
Publicado: (2014)

Application of Semiautomatic Fetal Intelligent Navigation Echocardiography (FINE) in Twin Pregnancies: Half the Work or Twice the Effort?
por: Gembicki, Michael, et al.
Publicado: (2023)

Possible Vertical Transmission From an Unsuspected SARS-CoV-2-Infected Mother to Her Newborn
por: Naseh, Ali, et al.
Publicado: (2021)

The Predictive Value of PITX2 DNA Methylation for High-Risk Breast Cancer Therapy: Current Guidelines, Medical Needs, and Challenges
por: Aubele, Michaela, et al.
Publicado: (2017)

Comparison of risk assessment in 1652 early ER positive, HER2 negative breast cancer in a real-world data set: classical pathological parameters vs. 12-gene molecular assay (EndoPredict)
por: Jank, Paul, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_njjnh44bm1ar9gqrj2j8o3iseh